Cellectar Biosciences
CLRB • NASDAQ
Cellectar Biosciences is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO James V. Caruso, with a market cap of $11.4M.
CEOJames V. Caruso
Next Earnings
Upcoming earnings announcement for Cellectar Biosciences
Date
Tuesday, May 12, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.67
Earnings History
Past 12 earnings reports for Cellectar Biosciences
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | Q4 2025 | -$0.53Est: -$1.21 | +56.2% | - | — |  10-K |
| Nov 13, 2025 | Q3 2025 | -$1.41Est: -$2.28 | +38.2% | - | — | 10-Q |
| Aug 14, 2025 | Q2 2025 | -$3.39Est: -$3.66 | +7.4% | - | — | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.14Est: -$0.16 | +12.5% | - | — | 10-Q |
| Mar 13, 2025 | Q4 2024 | -$0.01Est: -$0.35 | +97.1% | - | — | 10-K |
| Nov 18, 2024 | Q3 2024 | -$0.40Est: -$0.37 | -8.1% | - | — | 10-Q |
| Oct 29, 2024 | Q2 2024 | -$0.18Est: -$1.00 | +82.0% | - | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.74Est: -$0.72 | -2.8% | - | — | 10-Q |
| Mar 27, 2024 | Q4 2023 | -$0.40Est: -$0.59 | +32.2% | - | — | — |
| Nov 13, 2023 | Q3 2023 | -$0.82Est: -$0.44 | -86.4% | - | — | — |
| Aug 14, 2023 | Q2 2023 | -$0.73Est: -$0.69 | -5.8% | - | — | — |
| May 4, 2023 | Q1 2023 | -$0.76Est: -$0.72 | -5.6% | - | — | — |